Karen Vigil, MD
Basic profileThe University of Texas Health Science Center at Houston
Karen Vigil is an Infectious Disease physician affiliated with The University of Texas Health Science Center at Houston. OpenAlex indexes 90 publications with 961 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
Suite 600
Houston, TX 770303000
Telephone
832-325-7070Registry record last updated 15 Jul 2010.
Clinical trials
- Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Sponsor: The University of Texas Health Science Center, Houston
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202518 payments$15,302openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20253 payments
- Gilead Sciences, Inc.Program year202423 payments$19,339openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
40.1%Statin13.9%Atorvastatin Calcium89%Rosuvastatin Calcium6%Pravastatin Sodium5%Part D<11 patientsCalcium channel blocker8.3%Amlodipine Besylate56%Nifedipine Er44%Part D≥21 patients+ 6 more classes in this area
Anti-infectives
24.9%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor7.7%Tivicay53%Dovato47%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor5%Triumeq50%Descovy38%Abacavir13%Part D<11 patients+ 8 more classes in this area
Nervous system
9%Gabapentinoids5.4%Gabapentin89%Pregabalin11%Part D<11 patientsOpioid Agonist1.3%Tramadol Hcl100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Arnett, MD
The University of Texas Health Science Center at Houston
Ali Marian, MD
The University of Texas Health Science Center at Houston
Anjail Sharrief, MD
The University of Texas Health Science Center at Houston
Heidi Russell, MD
The University of Texas Health Science Center at Houston
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”